Search

Your search keyword '"Meserve, Joseph"' showing total 148 results
Start Over Author "Meserve, Joseph"
148 results on '"Meserve, Joseph"'

1. Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohns Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis.

Author

Jew, Michael, Meserve, Joseph, Eisenstein, Samuel, Jairath, Vipul, McCurdy, Jeffrey, and Singh, Siddharth

Subjects
Perianal fistula, biologics, ostomy, surgery, Humans, Crohn Disease, Feces, Proctectomy, Proctitis, Biological Products
Abstract

BACKGROUND AND AIMS: We evaluated short- and long-term outcomes of temporary faecal diversion [FD] for management of refractory Crohns disease [CD], focusing on outcomes in the biologic era. METHODS: Through a systematic literature review until March 15, 2023, we identified 33 studies [19 conducted in the biologic era] that evaluated 1578 patients with perianal and/or distal colonic CD who underwent temporary FD [with intent of restoring bowel continuity] and reported long-term outcomes [primary outcome: successful restoration of bowel continuity, defined as remaining ostomy-free after reconnection at a minimum of 6 months after diversion or at the end of follow-up]. We calculated pooled rates (with 95% confidence interval [CI]) using random effects meta-analysis, and examined factors associated with successful restoration of bowel continuity. RESULTS: Overall, 61% patients [95% CI, 52-68%; 50% in biologic era] experienced clinical improvement after FD. Stoma takedown was attempted in 34% patients [28-41%; 37% in biologic era], 6-18 months after diversion. Among patients where bowel restoration was attempted, 63% patients [54-71%] had successful restoration of bowel continuity, and 26% [20-34%] required re-diversion. Overall, 21% patients [17-27%; 24% in biologic era] who underwent FD were successfully restored; 34% patients [30-39%; 31% in biologic era] required proctectomy with permanent ostomy. On meta-regression, post-diversion biologic use and absence of proctitis was associated with successful bowel restoration after temporary FD in contemporary studies. CONCLUSION: In the biologic era, temporary FD for refractory perianal and/or distal colonic CD improves symptoms in half the patients, and bowel continuity can be successfully restored in a quarter of patients.

Published
2024

2. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn’s Disease: A Systematic Review and Meta-analysis

Author

Meserve, Joseph, Ma, Christopher, Dulai, Parambir S, Jairath, Vipul, and Singh, Siddharth

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Crohn's Disease, Inflammatory Bowel Disease, Digestive Diseases, Autoimmune Disease, 6.1 Pharmaceuticals, Adult, Humans, Ustekinumab, Crohn Disease, Remission Induction, Endoscopy, Treatment Outcome, Biologics, Dose Adjustment, Pharmacokinetics, Therapeutic Drug Monitoring, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsPatients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalation. We conducted a systematic review and meta-analysis examining the effectiveness of reinduction and/or dose interval shortening of ustekinumab in patients with active CD despite standard induction and maintenance.MethodsThrough a systematic literature search through March 31, 2021, we identified 15 cohort studies in 925 adults with CD with inadequate response or loss of response to standard dose ustekinumab, underwent dose escalation (reinduction and/or dose interval shortening to

Published
2022

3. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn’s Disease: A Multicenter Study

Author

McCurdy, Jeffrey D., Munir, Javeria, Parlow, Simon, Reid, Jacqueline, Yanofsky, Russell, Alenezi, Talal, Meserve, Joseph, Becker, Brenda, Lahijanian, Zubin, Eddin, Anas Hussam, Mallick, Ranjeeta, Ramsay, Tim, Rosenfeld, Greg, Bessissow, Ali, Bessissow, Talat, Jairath, Vipul, Singh, Siddharth, Bruining, David H., and Macdonald, Blair

Published
2024
Full Text
View/download PDF

4. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

Author

Lukin, Dana, Faleck, David, Xu, Ronghui, Zhang, Yiran, Weiss, Aaron, Aniwan, Satimai, Kadire, Siri, Tran, Gloria, Rahal, Mahmoud, Winters, Adam, Chablaney, Shreya, Koliani-Pace, Jenna L, Meserve, Joseph, Campbell, James P, Kochhar, Gursimran, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Boland, Brigid, Singh, Siddharth, Hirten, Robert, Ungaro, Ryan, Lasch, Karen, Shmidt, Eugenia, Jairath, Vipul, Hudesman, David, Chang, Shannon, Swaminath, Arun, Shen, Bo, Kane, Sunanda, Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frederic, Siegel, Corey A, Sandborn, William J, and Dulai, Parambir S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Digestive Diseases, Inflammatory Bowel Disease, Patient Safety, Clinical Research, Cancer, Autoimmune Disease, 6.1 Pharmaceuticals, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Gastrointestinal Agents, Humans, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, Health Outcomes, Comparative Research, Biologics, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsWe aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice.MethodsA multicenter, retrospective, observational cohort study (May 2014 to December 2017) of ulcerative colitis patients treated with vedolizumab or TNF-antagonist therapy. Propensity score weighted comparisons for development of serious adverse events and achievement of clinical remission, steroid-free clinical remission, and steroid-free deep remission. A priori determined subgroup comparisons in TNF-antagonist-naïve and -exposed patients, and for vedolizumab against infliximab and subcutaneous TNF-antagonists separately.ResultsA total of 722 (454 vedolizumab, 268 TNF antagonist) patients were included. Vedolizumab-treated patients were more likely to achieve clinical remission (hazard ratio [HR], 1.651; 95% confidence interval [CI], 1.229-2.217), steroid-free clinical remission (HR, 1.828; 95% CI, 1.135-2.944), and steroid-free deep remission (HR, 2.819; 95% CI, 1.496-5.310) than those treated with TNF antagonists. Results were consistent across subgroup analyses in TNF-antagonist-naïve and -exposed patients, and for vedolizumab vs infliximab and vs subcutaneous TNF-antagonist agents separately. Overall, there were no statistically significant differences in the risk of serious adverse events (HR, 0.899; 95% CI, 0.502-1.612) or serious infections (HR, 1.235; 95% CI, 0.608-2.511) between vedolizumab-treated and TNF-antagonist-treated patients. However, in TNF-antagonist-naïve patients, vedolizumab was less likely to be associated with serious adverse events than TNF antagonists (HR, 0.192; 95% CI, 0.049-0.754).ConclusionsTreatment of ulcerative colitis with vedolizumab is associated with higher rates of remission than treatment with TNF-antagonist therapy in routine practice, and lower rates of serious adverse events in TNF-antagonist-naïve patients.

Published
2022

5. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases

Author

Meserve, Joseph, Luo, Jiyu, Zhu, Wenhong, Veeravalli, Nina, Bandoli, Gretchen, Chambers, Christina D, Singh, Abha G, Boland, Brigid S, Sandborn, William J, Mahadevan, Uma, and Singh, Siddharth

Subjects
Paediatrics, Biomedical and Clinical Sciences, Clinical Research, Digestive Diseases, Prevention, Autoimmune Disease, Perinatal Period - Conditions Originating in Perinatal Period, Arthritis, Pediatric, Preterm, Low Birth Weight and Health of the Newborn, 6.1 Pharmaceuticals, Reproductive health and childbirth, Inflammatory and immune system, Good Health and Well Being, Abnormalities, Drug-Induced, Adult, Biological Factors, Congenital Abnormalities, Female, Humans, Immune System Diseases, Immunosuppressive Agents, Infant, Low Birth Weight, Infant, Newborn, Inflammation, Male, Paternal Exposure, Pregnancy, Premature Birth, Prenatal Exposure Delayed Effects, Retrospective Studies, Teratogenicity, Paternal, Crohn's Disease, Immunomodulators, Infliximab, Crohn’s Disease, Clinical Sciences, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsWe conducted a retrospective cohort study to inform the safety of exposure to immunosuppressive and/or biologic agents around conception in expectant fathers with immune-mediated inflammatory diseases (IMIDs) on birth outcomes.MethodsUsing a deidentified administrative claims database (OptumLabs Data Warehouse), we identified 7453 expectant fathers with IMIDs (inflammatory bowel diseases, rheumatoid arthritis, psoriasis/psoriatic arthritis, and ankylosing spondylitis) linked to newborns with periconception medication exposure between 38 and 60 weeks before the newborn birth date (34-58 weeks prior for preterm newborns) and neonatal follow-up for 3 months after the birth date. Through logistic regression adjusting for paternal age and race (and, in a subset, for maternal age, race, presence of IMIDs, and nonsingleton births), we compared the risk of major congenital malformations (primary outcome) and preterm birth and low birth weight in fathers exposed to thiopurines (n = 461), methotrexate (n = 171), tumor necrosis factor (TNF) α antagonists (n = 1082), or non-TNF-targeting biologic agents (n = 132) vs fathers not exposed to any of these medications (n = 5607).ResultsAs compared to unexposed fathers (3.4% prevalence of major congenital malformations), exposure to thiopurines (relative risk [RR], 1.12; 95% confidence interval [CI], 0.66-1.76), methotrexate (RR, 0.67; 95% CI, 0.21-1.55), TNF-α antagonists (RR, 1.14; 95% CI, 0.81-1.57), and non-TNF-targeting biologic agents (RR, 1.75; 95% CI, 0.80-3.24) was not associated with increased risk of major congenital malformations. No association was observed between paternal medication exposure and risk of preterm birth or low birth weight. Results were stable on subanalyses of linked father-mother-newborn triads.ConclusionsIn a large cohort study of 7453 expectant fathers with IMIDs, exposure to immunosuppressive or biologic agents around conception was not associated with increased risk of adverse birth outcomes.

Published
2021

6. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Author

Dulai, Parambir S, Singh, Siddharth, Casteele, Niels Vande, Meserve, Joseph, Winters, Adam, Chablaney, Shreya, Aniwan, Satimai, Shashi, Preeti, Kochhar, Gursimran, Weiss, Aaron, Koliani-Pace, Jenna L, Gao, Youran, Boland, Brigid S, Chang, John T, Faleck, David, Hirten, Robert, Ungaro, Ryan, Lukin, Dana, Sultan, Keith, Hudesman, David, Chang, Shannon, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Shmidt, Eugenia, Swaminath, Arun, Gupta, Nitin, Rosario, Maria, Jairath, Vipul, Guizzetti, Leonardo, Feagan, Brian G, Siegel, Corey A, Shen, Bo, Kane, Sunanda, Loftus, Edward V, Sandborn, William J, Sands, Bruce E, Colombel, Jean-Frederic, Lasch, Karen, and Cao, Charlie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Digestive Diseases, Autoimmune Disease, Inflammatory Bowel Disease, Clinical Research, 6.1 Pharmaceuticals, Oral and gastrointestinal, Good Health and Well Being, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Gastrointestinal Agents, Humans, Remission Induction, Treatment Outcome, Prognostic Factor, Response to Treatment, Personalized Medicine, Biologic, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients with UC who received vedolizumab induction and maintenance therapy (derivation cohort), to identify factors associated with corticosteroid-free remission (full Mayo score of 2 or less, no subscore above 1). We used these factors to develop a model to predict outcomes of treatment, which we called the vedolizumab CDST. We evaluated the correlation between exposure and efficacy. We validated the CDST in using data from 199 patients treated with vedolizumab in routine practice in the United States from May 2014 through December 2017.ResultsAbsence of exposure to a tumor necrosis factor (TNF) antagonist (+3 points), disease duration of 2 y or more (+3 points), baseline endoscopic activity (moderate vs severe) (+2 points), and baseline albumin concentration (+0.65 points per 1 g/L) were independently associated with corticosteroid-free remission during vedolizumab therapy. Patients in the derivation and validation cohorts were assigned to groups of low (CDST score, 26 points or less), intermediate (CDST score, 27-32 points), or high (CDST score, 33 points or more) probability of vedolizumab response. We observed a statistically significant linear relationship between probability group and efficacy (area under the receiver operating characteristic curve, 0.65), as well as drug exposure (P < .001) in the derivation cohort. In the validation cohort, a cutoff value of 26 points identified patients who did not respond to vedolizumab with high sensitivity (93%); only the low and intermediate probability groups benefited from reducing intervals of vedolizumab administration due to lack of response (P = .02). The vedolizumab CDST did not identify patients with corticosteroid-free remission during TNF antagonist therapy.ConclusionsWe used data from a trial of patients with UC to develop a scoring system, called the CDST, which identified patients most likely to enter corticosteroid-free remission during vedolizumab therapy, but not anti-TNF therapy. We validated the vedolizumab CDST in a separate cohort of patients in clinical practice. The CDST identified patients most likely to benefited from reducing intervals of vedolizumab administration due to lack of initial response. ClinicalTrials.gov no: NCT00783718.

Published
2020

7. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis

Author

Faleck, David M, Winters, Adam, Chablaney, Shreya, Shashi, Preeti, Meserve, Joseph, Weiss, Aaron, Aniwan, Satimai, Koliani-Pace, Jenna L, Kochhar, Gursimran, Boland, Brigid S, Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Kesar, Varun, Lasch, Karen, Luo, Michelle, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Hudesman, David, Chang, Shannon, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Siegel, Corey A, Shen, Bo, Sandborn, William J, Kane, Sunanda, Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frederic, Dulai, Parambir S, and Ungaro, Ryan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Crohn's Disease, Clinical Research, Autoimmune Disease, Digestive Diseases, Inflammatory Bowel Disease, Oral and gastrointestinal, Adult, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Crohn Disease, Endoscopy, Digestive System, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Registries, Remission Induction, Retrospective Studies, Time Factors, Young Adult, Integrin, Monoclonal Antibody Therapy, Time, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration.MethodsWe analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes.ResultsWithin 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC.ConclusionsPatients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.

Published
2019

9. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Author

Meserve, Joseph, Aniwan, Satimai, Koliani-Pace, Jenna L., Shashi, Preeti, Weiss, Aaron, Faleck, David, Winters, Adam, Chablaney, Shreva, Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Bohm, Matthew, Sagi, Sashidhar Varma, Fischer, Monika, Lukin, Dana, Hudesman, David, Chang, Shannon, Gao, Youran, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V., Jr., Shen, Bo, Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., and Dulai, Parambir S.

Published
2019
Full Text
View/download PDF

11. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

Author

Dulai, Parambir S., Boland, Brigid S., Singh, Siddharth, Chaudrey, Khadija, Koliani-Pace, Jenna L., Kochhar, Gursimran, Parikh, Malav P., Shmidt, Eugenia, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Whitehead, Diana, Hirten, Robert, Winters, Adam C., Katta, Leah G., Peerani, Farhad, Narula, Neeraj, Sultan, Keith, Swaminath, Arun, Bohm, Matthew, Lukin, Dana, Hudesman, David, Chang, John T., Rivera-Nieves, Jesus, Jairath, Vipul, Zou, G.Y., Feagan, Brian G., Shen, Bo, Siegel, Corey A., Loftus, Edward V., Jr., Kane, Sunanda, Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Lasch, Karen, and Cao, Charlie

Published
2018
Full Text
View/download PDF

13. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Author

Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., and Dulai, Parambir S.

Published
2018
Full Text
View/download PDF

15. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes

Author

Koliani-Pace, Jenna L, Singh, Siddharth, Luo, Michelle, Hirten, Robert, Aniwan, Satimai, Kochhar, Gursimran, Chang, Shannon, Lukin, Dana, Gao, Youran, Bohm, Matthew, Swaminath, Arun, Gupta, Nitin, Shmidt, Eugenia, Meserve, Joseph, Winters, Adam, Chablaney, Shreya, Faleck, David M, Yang, Jiao, Huang, Zhongwen, Boland, Brigid S, Shashi, Preeti, Weiss, Aaron, Hudesman, David, Varma, Sashidhar, Fischer, Monika, Sultan, Keith, Shen, Bo, Kane, Sunanda, Loftus, Edward V, Jr, Sands, Bruce E, Colombel, Jean-Frederic, Sandborn, William J, Lasch, Karen, Siegel, Corey A, and Dulai, Parambir S

Published
2019
Full Text
View/download PDF

16. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

Author

Shmidt, Eugenia, Kochhar, Gursimran, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Chaudrey, Khadija, Koliani-Pace, Jenna L, Hirten, Robert, Faleck, David, Barocas, Morris, Luo, Michelle, Lasch, Karen, Boland, Brigid S, Singh, Siddharth, Vande Casteele, Niels, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V, Jr, Sandborn, William J, Siegel, Corey A, Sands, Bruce E, Colombel, Jean-Frederic, Shen, Bo, and Dulai, Parambir S

Published
2018
Full Text
View/download PDF

19. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease

Author

Dulai, Parambir S., Amiot, Aurélien, Peyrin-Biroulet, Laurent, Jairaith, Vipul, Serrero, Mélanie, Filippi, Jérome, Singh, Siddharth, Pariente, Benjamin, Loftus, Edward V., Roblin, Xavier, Kane, Sunanda, Buisson, Anthony, Siegel, Corey A., Bouhnik, Yoram, Sandborn, William J., Lasch, Karen, Rosario, Maria, Feagan, Brian G., Bojic, Daniela, Trang-Poisson, Caroline, Shen, Bo, Altwegg, Romain, Sands, Bruce E., Colombel, Jean-Frederic, Carbonnel, Franck, Kochhar, Gursimran, Meserve, Joseph, Barsky, Maria, Boland, Brigid S., Gagniere, Charlotte, Bigard, Marc-André, Zallot, Camille, Grimaud, Jean-Charles, Hebuterne, Xavier, Nachury, Maria, Desreumaux, Pierre, del Tedesco, Emilie, Bommelaer, Gilles, Koliani-Pace, Jenna L., Stefanescu, Carmen, Boureille, Arnaud, Hirten, Robert, Ungaro, Ryan, Vaysse, Thibaud, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Hudesman, David, Chang, Shannon, Bourrier, Anne, Seksik, Philippe, Beaugerie, Laurent, Cosnes, Jacques, Sokol, Harry, Landman, Cécilia, Lukin, Dana, Weiss, Aaron, Marteau, Philippe, Dray, Xavier, Nancey, Stephane, Boschetti, Gilles, Laharie, David, Poullenot, Florian, Allez, Matthieu, Gornet, Jean-Marc, Baudry, Clautilde, Savoye, Guillaume, Moreau, Jacques, Vuitton, Lucine, Koch, Stéphane, Viennot, Stéphanie, Aubourg, Alexandre, Picon, Laurence, Pelletier, Anne-Laure, Sickersen, Gaelle, Bouguen, Guillaume, Abitbol, Vered, Chaussade, Stanislas, Nahon, Stéphane, Fumery, Mathurin, Winkfield, Betsy, Brixi-Benmansour, Hedia, Gincul, Rodica, Barberis, Jean-Christophe, Bonaz, Bruno, Michiels, Christophe, Zerbib, Frank, Beauregard, Marie Bourrier, Locher, Christophe, Davin-Couve, Sophie, Poirette, Armelle, Guillem, Laurence, Stetiu-Mocanu, Monica, Philippe, Beau, Beorchia, Sylvain, Al Qaddi, Jawad, Swaminath, Arun, Observ-Ibd, Getaid, Collaboration, Victory Cohorts, Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), University of Western Ontario (UWO), Centre Hospitalier Universitaire de Nice (CHU Nice), University of California [San Diego] (UC San Diego), University of California (UC), Mayo Clinic [Rochester], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Dartmouth Hitchcock Medical Center, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CICECO Department of chemistry and physics, Universidade de Aveiro, Robarts Research Institute [Canada], Centre hospitalier universitaire de Nantes (CHU Nantes), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Columbia University Irving Medical Center (CUIMC), Icahn School of Medicine at Mount Sinai [New York] (MSSM), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance Publique - Hôpitaux de Marseille (APHM), Université Côte d'Azur (UCA), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Service de neurologie [Le Kremlin Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Indiana University - Purdue University Indianapolis (IUPUI), Indiana University System, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipes Traitement de l'Information et Systèmes (ETIS - UMR 8051), Ecole Nationale Supérieure de l'Electronique et de ses Applications (ENSEA)-Centre National de la Recherche Scientifique (CNRS)-CY Cergy Paris Université (CY), Sorbonne Université (SU), Autophagie infection et immunité - Autophagy Infection Immunity (APY), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Hôpital Haut-Lévêque [CHU Bordeaux], Hopital Saint-Louis [AP-HP] (AP-HP), Service d'Endocrinologie, Diabétologie, Maladies Métaboliques, Hôpital Avicenne, Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501), Université de Tours (UT), Hépato-Gastro-Onco-Entérologie [CHRU de Tours], Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Service d'hépato-gastro-entérologie [Hôpital Saint-Louis, APHP], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Cochin [AP-HP], Université Sorbonne Paris Cité (USPC), Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire [Grenoble] (CHU), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Grand Hôpital de l'Est Francilien (GHEF), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de gastroentérologie [CHU Saint-Etienne], Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Nicolle [Rouen]-CHU Rouen, and CHU Toulouse [Toulouse]

Subjects
Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Disease, Antibodies, Monoclonal, Humanized, Antiviral Agents, Clinical decision support system, Vedolizumab, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Internal medicine, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Young adult, Optimising Vedolizumab in Crohn's Disease, Crohn's disease, Hepatology, business.industry, Patient Selection, Gastroenterology, Middle Aged, Decision Support Systems, Clinical, medicine.disease, Hepatitis C, Treatment Outcome, Calibration, Original Article, Female, 030211 gastroenterology & hepatology, Observational study, Onset of action, Drug Monitoring, business, Algorithms, medicine.drug, Cohort study
Abstract

International audience; Background A clinical decision support tool (CDST) has been validated for predicting treatment effectiveness of vedolizumab (VDZ) in Crohn's disease. Aim To assess the utility of this CDST for predicting exposure-efficacy and disease outcomes. Methods Using data from three independent datasets (GEMINI, GETAID and VICTORY), we assessed clinical remission rates and measured VDZ exposure, rapidity of onset of action, response to dose optimisation and progression to surgery by CDST-defined response groups (low, intermediate and high). Results A linear relationship existed between CDST-defined groups, measured VDZ exposure, rapidity of onset of action and efficacy in GEMINI through week 52 (P < 0.001 at all time points across three CDST-defined groups). In GETAID, CDST predicted differences in clinical remission at week 14 (AUC = 0.68) and rapidity of onset of action (P = 0.04) between probability groups. The high-probability patients did not benefit from shortening of infusion intervals, and differences in onset of action between the high-intermediate and low-probability groups within GETAID were no longer significant when including low-probability patients who received a week 10 infusion. CDST predicted a twofold increase in surgery risk over 12 months of VDZ therapy among low- to intermediate-probability vs high-probability patients (adjusted HR 2.06, 95% CI 1.33-3.21). Conclusions We further extended the clinical utility of a previously validated VDZ CDST, which accurately predicts at baseline exposure-efficacy relationships and rapidity of onset of action and could be used to help identify patients who would most benefit from interval shortening and those most likely to require surgery while on active therapy.

Published
2019
Full Text
View/download PDF

29. 334 – Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis

Author

Dulai, Parambir S., primary, Singh, Siddharth, additional, Casteele, Niels Vande, additional, Meserve, Joseph, additional, Winters, Adam C., additional, Chablaney, Shreya, additional, Aniwan, Satimai, additional, Shashi, Preeti, additional, Kochhar, Gursimran, additional, Weiss, Aaron, additional, Koliani-Pace, Jenna, additional, Gao, Youran, additional, Boland, Brigid S., additional, Chang, John T., additional, Faleck, David, additional, Hirten, Robert, additional, Ungaro, Ryan C., additional, Lukin, Dana, additional, Keith, Sultan, additional, Hudesman, David, additional, Chang, Shannon, additional, Bohm, Matthew, additional, Varma, Sashidhar, additional, Fischer, Monika, additional, Shmidt, Eugenia, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Rosario, Maria, additional, Jairath, Vipul, additional, Guizzetti, Leonardo, additional, Feagan, Brian G., additional, Siegel, Corey A., additional, Shen, Bo, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Sandborn, William J., additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Lasch, Karen, additional, and Cao, Charlie, additional

Published
2019
Full Text
View/download PDF

30. Mo1916 – Effectiveness and Safety of Ustekinumab for Crohn’s Disease in Routine Clinical Practice

Author

Lynn, Amanda M., primary, Barsky, Maria, additional, Ahmed, Waseem, additional, Zullow, Samantha, additional, Jairath, Vipul, additional, Kochhar, Gursimran, additional, Weiss, Aaron, additional, Phipps, Meaghan, additional, Agrawal, Mansi, additional, Click, Benjamin H., additional, Meserve, Joseph, additional, Swaminath, Arun, additional, Bohm, Matthew, additional, Sagi, Sashidhar, additional, Fischer, Monika, additional, Hudesman, David, additional, Chang, Shannon, additional, Lawlor, Garrett, additional, Lukin, Dana J., additional, Ullman, Thomas A., additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Sandborn, William J., additional, Regueiro, Miguel D., additional, Shen, Bo, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, and Dulai, Parambir S., additional

Published
2019
Full Text
View/download PDF

31. Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases.

Author

Meserve, Joseph, Facciorusso, Antonio, Holmer, Ariela K., Annese, Vito, Sandborn, William J., and Singh, Siddharth

Subjects
*IMMUNE checkpoint inhibitors, *INFLAMMATORY bowel diseases, *PROGRAMMED cell death 1 receptors, *DISEASE relapse, *IMMUNOLOGIC diseases, *CORTICOSTEROIDS
Abstract

Summary: Background: Immune checkpoint inhibitors may variably impact patients with pre‐existing autoimmune diseases. Aims: To evaluate the risks and outcomes of adverse events in patients with pre‐existing inflammatory bowel diseases treated with immune checkpoint inhibitors. Methods: Through a systematic literature review up until July 31, 2020, we identified 12 studies reporting the impact of immune checkpoint inhibitors in 193 patients with inflammatory bowel disease. Outcomes of interest were relapse of inflammatory bowel disease, need for corticosteroids and/or biologics to manage inflammatory bowel disease relapse, and discontinuation of immune checkpoint inhibitors. We calculated pooled rates (with 95% confidence intervals [CI]) using random effects meta‐analysis, and examined risk factors associated with adverse outcomes through qualitative synthesis of individual studies. Results: On meta‐analysis, 40% patients (95% CI, 26%‐55%) experienced relapse of inflammatory bowel disease with immune checkpoint inhibitors. Among patients who experienced relapse, 76% (95% CI, 65%‐85%) required corticosteroids, and 37% (95% CI, 22%‐53%) required biologic therapy. Overall, 35% patients (95% CI, 17%‐57%) with inflammatory bowel disease discontinued immune checkpoint inhibitors. Gastrointestinal perforation and abdominal surgery due to immune checkpoint inhibitor complications occurred in <5% patients. In a large study, inhibitors of cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) were associated with a higher risk of relapse than programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors. Conclusions: Approximately 40% of patients with pre‐existing inflammatory bowel diseases experience relapse with immune checkpoint inhibitors, with most relapsing patients requiring corticosteroids and one‐third requiring biologics. CTLA‐4 inhibitors may be associated with higher risk of relapse. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Shifts in Vedolizumab Utilization Across the United States Are Associated With Improved Outcomes

Author

Koliani-Pace, Jenna, primary, Singh, Siddharth, additional, Hirten, Robert, additional, Aniwan, Satimai, additional, Kochhar, Gursimran, additional, Chang, Shannon, additional, Lukin, Dana J., additional, Gao, Youran, additional, Bohm, Matthew, additional, Swaminath, Arun, additional, Kesar, Varun, additional, Gupta, Nitin, additional, Shmidt, Eugenia, additional, Meserve, Joseph, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Faleck, David, additional, Boland, Brigid S., additional, Shashi, Preeti, additional, Weiss, Aaron, additional, Hudesman, David, additional, Varma, Sashidhar, additional, Fischer, Monika, additional, Sultan, Keith, additional, Shen, Bo, additional, Kane, Sunanda, additional, Loftus, Edward V., additional, Sands, Bruce E., additional, Colombel, Jean-Frederic, additional, Sandborn, William J., additional, Lasch, Karen, additional, Luo, Michelle, additional, Yang, Jiao, additional, Siegel, Corey, additional, and Dulai, Parambir S., additional

Published
2018
Full Text
View/download PDF

33. Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Author

Narula, Neeraj, primary, Peerani, Farhad, additional, Meserve, Joseph, additional, Kochhar, Gursimran, additional, Chaudrey, Khadija, additional, Hartke, Justin, additional, Chilukuri, Prianka, additional, Koliani-Pace, Jenna, additional, Winters, Adam, additional, Katta, Leah, additional, Shmidt, Eugenia, additional, Hirten, Robert, additional, Faleck, David, additional, Parikh, Malav P., additional, Whitehead, Diana, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Sagi, Sashidhar Varma, additional, Fischer, Monika, additional, Chang, Shannon, additional, Barocas, Morris, additional, Luo, Michelle, additional, Lasch, Karen, additional, Bohm, Matthew, additional, Lukin, Dana, additional, Sultan, Keith, additional, Swaminath, Arun, additional, Hudesman, David, additional, Gupta, Nitin, additional, Shen, Bo, additional, Kane, Sunanda, additional, Loftus, Edward V., additional, Siegel, Corey A., additional, Sands, Bruce E., additional, Colombel, Jean-Frederic, additional, Sandborn, William J., additional, and Dulai, Parambir S., additional

Published
2018
Full Text
View/download PDF

34. 277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Author

Lukin, Dana J., primary, Weiss, Aaron, additional, Aniwan, Satimai, additional, Kadire, Siri, additional, Tran, Gloria, additional, Rahal, Mahmoud, additional, Faleck, David, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Meserve, Joseph, additional, Kochhar, Gursimran, additional, Shashi, Preeti, additional, Koliani-Pace, Jenna L., additional, Bohm, Matthew, additional, Sagi, Sashivar, additional, Fischer, Monika, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Hudesman, David, additional, Chang, Shannon, additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Shen, Bo, additional, Sands, Bruce E., additional, Sandborn, William J., additional, Colombel, Jean Frederic, additional, Siegel, Corey A., additional, and Dulai, Parambir, additional

Published
2018
Full Text
View/download PDF

35. Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis

Author

Hudesman, David, primary, Chang, Shannon, additional, Shashi, Preeti, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Meserve, Joseph, additional, Weiss, Aaron, additional, Aniwan, Satimai, additional, Faleck, David, additional, Koliani-Pace, Jenna L., additional, Kochhar, Gursimran, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Lasch, Karen, additional, Luo, Michelle, additional, Bohm, Matthew, additional, Sagi, Sashivar, additional, Fischer, Monika, additional, Lukin, Dana J., additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Siegel, Corey A., additional, Shen, Bo, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Sands, Bruce E., additional, Sandborn, William J., additional, Colombel, Jean Frederic, additional, and Dulai, Parambir, additional

Published
2018
Full Text
View/download PDF

36. 328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

Author

Faleck, David, primary, Shashi, Preeti, additional, Meserve, Joseph, additional, Rahal, Mahmoud, additional, Kadire, Siri, additional, Tran, Gloria, additional, Weiss, Aaron, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Aniwan, Satimai, additional, Koliani-Pace, Jenna L., additional, Kochhar, Gursimran, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Lasch, Karen, additional, Luo, Michelle, additional, Bohm, Matthew, additional, Sagi, Sashivar, additional, Fischer, Monika, additional, Hudesman, David, additional, Chang, Shannon, additional, Lukin, Dana J., additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Siegel, Corey A., additional, Shen, Bo, additional, Sandborn, William J., additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, and Dulai, Parambir, additional

Published
2018
Full Text
View/download PDF

37. Mo1867 - Shorter Disease Duration is Associated with Higher Response Rates to Vedolizumab in Crohn's Disease but not Ulcerative Colitis: A Multi-Center Consortium Analysis

Author

Faleck, David, primary, Winters, Adam, additional, Chablaney, Shreya, additional, Shashi, Preeti, additional, Meserve, Joseph, additional, Weiss, Aaron, additional, Aniwan, Satimai, additional, Koliani-Pace, Jenna L., additional, Kochhar, Gursimran, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Lasch, Karen, additional, Luo, Michelle, additional, Bohm, Matthew, additional, Sagi, Sashivar, additional, Fischer, Monika, additional, Hudesman, David, additional, Chang, Shannon, additional, Lukin, Dana J., additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Siegel, Corey A., additional, Shen, Bo, additional, Sandborn, William J., additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Dulai, Parambir, additional, and Ungaro, Ryan C., additional

Published
2018
Full Text
View/download PDF

38. Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Author

Bohm, Matthew, primary, Sagi, Sashivar, additional, Fischer, Monika, additional, Kadire, Siri, additional, Tran, Gloria, additional, Rahal, Mahmoud, additional, Aniwan, Satimai, additional, Meserve, Joseph, additional, Weiss, Aaron, additional, Kochhar, Gursimran, additional, Shashi, Preeti, additional, Faleck, David, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Koliani-Pace, Jenna L., additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Lasch, Karen, additional, Luo, Michelle, additional, Hudesman, David, additional, Chang, Shannon, additional, Lukin, Dana J., additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Siegel, Corey A., additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Sands, Bruce E., additional, Sandborn, William J., additional, Colombel, Jean Frederic, additional, Shen, Bo, additional, and Dulai, Parambir, additional

Published
2018
Full Text
View/download PDF

39. Sa1701 - A Multicenter Cohort Study to Assess the Safety of Vedolizumab for Inflammatory Bowel Disease

Author

Meserve, Joseph, primary, Aniwan, Satimai, additional, Koliani-Pace, Jenna, additional, Shashi, Preeti, additional, Weiss, Aaron, additional, Faleck, David, additional, Winters, Adam, additional, Chablaney, Shreya, additional, Kochhar, Gursimran, additional, Boland, Brigid S., additional, Singh, Siddharth, additional, Hirten, Robert, additional, Shmidt, Eugenia, additional, Bohm, Matthew, additional, Sagi, Sashivar, additional, Fischer, Monika, additional, Lukin, Dana J., additional, Hudesman, David, additional, Chang, Shannon, additional, Keith, Sultan, additional, Swaminath, Arun, additional, Gupta, Nitin, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Shen, Bo, additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Siegel, Corey A., additional, Sandborn, William J., additional, and Dulai, Parambir, additional

Published
2018
Full Text
View/download PDF

40. Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium

Author

Dulai, Parambir, primary, Meserve, Joseph D., additional, Hartke, Justin G., additional, Chilukuri, Prianka, additional, Chaudrey, Khadija, additional, Koliani-Pace, Jenna L., additional, Kochhar, Gursimran, additional, Parikh, Malav P., additional, Shmidt, Eugenia, additional, Hirten, Robert, additional, Luo, Michelle, additional, Barocas, Morris, additional, Lasch, Karen, additional, Sultan, Keith, additional, Swaminath, Arun, additional, Bohm, Matthew, additional, Lukin, Dana J., additional, Hudesman, David, additional, Shen, Bo, additional, Siegel, Corey A., additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, Singh, Siddharth, additional, Sandborn, William J., additional, and Boland, Brigid S., additional

Published
2017
Full Text
View/download PDF

41. Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium

Author

Koliani-Pace, Jenna L., primary, Chaudrey, Khadija, additional, Kochhar, Gursimran, additional, Shmidt, Eugenia, additional, Hartke, Justin G., additional, Chilukuri, Prianka, additional, Parikh, Malav P., additional, Hirten, Robert, additional, Meserve, Joseph D., additional, Luo, Michelle, additional, Barocas, Morris, additional, Lasch, Karen, additional, Singh, Siddharth, additional, Boland, Brigid S., additional, Sultan, Keith, additional, Swaminath, Arun, additional, Bohm, Matthew, additional, Lukin, Dana J., additional, Hudesman, David, additional, Sands, Bruce E., additional, Colombel, Jean Frederic, additional, Sandborn, William J., additional, Shen, Bo, additional, Kane, Sunanda V., additional, Siegel, Corey A., additional, Loftus, Edward V., additional, and Dulai, Parambir, additional

Published
2017
Full Text
View/download PDF

43. Disseminated Herpes Simplex Virus with Fulminant Hepatitis

Author

Rimawi, Bassam H., Meserve, Joseph, Rimawi, Ramzy H., Min, Zaw, and Gnann, John W.Jr.

Subjects
Article Subject, viruses
Abstract

Disseminated herpes simplex virus (HSV) is a rare cause of acute fulminant liver failure. We hereby present a case series of three patients with acute disseminated HSV with necrotizing hepatitis successfully treated with a week course of acyclovir. Early empiric administration of acyclovir therapy while awaiting confirmatory tests is critical in this potentially lethal disease.

Published
2015
Full Text
View/download PDF

45. Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice

Author

Dulai, Parambir S., primary, Peerani, Farhad, additional, Narula, Neeraj, additional, Chaudrey, Khadija, additional, Whitehead, Diana, additional, Hudesman, David, additional, Shmidt, Eugenia, additional, Lukin, Dana J., additional, Swaminath, Arun, additional, Nguyen, Nghia, additional, Meserve, Joseph, additional, Kane, Sunanda V., additional, Singh, Siddharth, additional, Boland, Brigid S., additional, Siegel, Corey A., additional, Loftus, Edward V., additional, Sandborn, William, additional, Sands, Bruce E., additional, and Colombel, Jean-Frederic, additional

Published
2016
Full Text
View/download PDF

46. Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice

Author

Peerani, Farhad, primary, Narula, Neeraj, additional, Dulai, Parambir S., additional, Chaudrey, Khadija, additional, Whitehead, Diana, additional, Hudesman, David, additional, Shmidt, Eugenia, additional, Lukin, Dana J., additional, Swaminath, Arun, additional, Nguyen, Nghia, additional, Meserve, Joseph, additional, Kane, Sunanda V., additional, Sandborn, William, additional, Sands, Bruce E., additional, Colombel, Jean-Frederic, additional, Siegel, Corey A., additional, Loftus, Edward V., additional, Singh, Siddharth, additional, and Boland, Brigid S., additional

Published
2016
Full Text
View/download PDF

47. Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium

Author

Chaudrey, Khadija, primary, Whitehead, Diana, additional, Dulai, Parambir S., additional, Peerani, Farhad, additional, Narula, Neeraj, additional, Hudesman, David, additional, Shmidt, Eugenia, additional, Lukin, Dana J., additional, Swaminath, Arun, additional, Nguyen, Nghia, additional, Meserve, Joseph, additional, Singh, Siddharth, additional, Boland, Brigid S., additional, Sandborn, William, additional, Sands, Bruce E., additional, Colombel, Jean-Frederic, additional, Kane, Sunanda V., additional, Loftus, Edward V., additional, and Siegel, Corey A., additional

Published
2016
Full Text
View/download PDF

48. Mo1785 - Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium

Author

Koliani-Pace, Jenna L., Chaudrey, Khadija, Kochhar, Gursimran, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Parikh, Malav P., Hirten, Robert, Meserve, Joseph D., Luo, Michelle, Barocas, Morris, Lasch, Karen, Singh, Siddharth, Boland, Brigid S., Sultan, Keith, Swaminath, Arun, Bohm, Matthew, Lukin, Dana J., Hudesman, David, Sands, Bruce E., Colombel, Jean Frederic, Sandborn, William J., Shen, Bo, Kane, Sunanda V., Siegel, Corey A., Loftus, Edward V., and Dulai, Parambir

Published
2017
Full Text
View/download PDF

49. Sa1853 - Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium

Author

Dulai, Parambir, Meserve, Joseph D., Hartke, Justin G., Chilukuri, Prianka, Chaudrey, Khadija, Koliani-Pace, Jenna L., Kochhar, Gursimran, Parikh, Malav P., Shmidt, Eugenia, Hirten, Robert, Luo, Michelle, Barocas, Morris, Lasch, Karen, Sultan, Keith, Swaminath, Arun, Bohm, Matthew, Lukin, Dana J., Hudesman, David, Shen, Bo, Siegel, Corey A., Sands, Bruce E., Colombel, Jean Frederic, Kane, Sunanda V., Loftus, Edward V., Singh, Siddharth, Sandborn, William J., and Boland, Brigid S.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results